References
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;
- Clark SB, Alsubait S. Non small. Cell Lung Cancer. 2021; PMID: 32965978.
- Justiz VA, Nessel TA, Zito PM. Immunotherapy. 2021; PMID: 30085588.
- Rolfo C, Caglevic C, Santarpia M, et al. Immunotherapy in NSCLC: a promising and revolutionary weapon. Adv Exp Med Biol. 2017;995:97–125.
- Jorgensen JT. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert Rev Mol Diagn. 2016;16(2):131–133.
- Nair L, Chung H, Basu U. Regulation of long non-coding RNAs and genome dynamics by the RNA surveillance machinery. Nat Rev Mol Cell Biol. 2020;21(3):123–136.
- Tsagakis I, Douka K, Birds I, et al. Long non-coding RNAs in development and disease: conservation to mechanisms. J Pathol. 2020;250(5):480–495.
- Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981.
- Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. Trends Cell Biol. 2018;28(4):287–301.
- Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172(3):393–407.
- Neve B, Jonckheere N, Vincent A, et al. Long non-coding RNAs: the tentacles of chromatin remodeler complexes. Cell Mol Life Sci. 2021;78(4):1139–1161.
- Zhu P, He F, Hou Y, et al. A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability. Oncogene. 2021;40(9):1609–1627.
- Yuan J, Song Y, Pan W, et al. LncRNA SLC26A4-AS1 suppresses the MRN complex-mediated DNA repair signaling and thyroid cancer metastasis by destabilizing DDX5. Oncogene. 2020;39(43):6664–6676.
- Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013;45(11):1392–1398.
- Prensner JR, Zhao S, Erho N, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014;15(13):1469–1480.
- Ji J, Xu R, Ding K, et al. Long noncoding RNA SChLAP1 forms a growth-promoting complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-κB signaling. Clin Cancer Res. 2019;25(22):6868–6881.
- Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):324r–328r.
- Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clin Immunol. 2021;226:108707.
- Shklovskaya E, Rizos H. Spatial and temporal changes in PD-L1 expression in cancer: the role of genetic drivers, tumor microenvironment and resistance to therapy. Int J Mol Sci. 2020;21(19):7139.
- Cha JH, Chan LC, Li CW, et al. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359–370.
- Chatterjee A, Rodger EJ, Ahn A, et al. Marked global DNA hypomethylation is associated with constitutive PD-L1 expression in melanoma. iScience. 2018;4:312–325.
- Venkatraman S, Meller J, Hongeng S, et al. Transcriptional regulation of cancer immune checkpoints: emerging strategies for immunotherapy. Vaccines (Basel) 2020;8(4):735.
- Zerdes I, Matikas A, Bergh J, et al. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene. 2018;37(34):4639–4661.
- Moore AE, Chenette DM, Larkin LC, et al. Physiological networks and disease functions of RNA-binding protein AUF1. Wiley Interdiscip Rev Rna. 2014;5(4):549–564.
- White EJ, Brewer G, Wilson GM. Post-transcriptional control of gene expression by AUF1: mechanisms, physiological targets, and regulation. Biochim Biophys Acta. 2013;1829(6-7):680–688.